Global funding for biotech startups is maintaining a nearly stable level in 2026, according to Crunchbase data, even as the artificial intelligence boom has redistributed venture capital across the startup ecosystem. The data expects total funding to remain close to the range of $36 billion to $40 billion recorded during the past few years.
This continuity does not mean that the sector is experiencing a strong expansion cycle. Total venture investment rose to a record level in the first half of the year, but a large portion of that increase went to two massive generative AI companies. In this context, biotech companies managed to secure a considerable share of the remaining capital, without their funding pace approaching the wave of enthusiasm surrounding AI.
AI Leads the Largest Rounds
Companies combining biotech and artificial intelligence received a prominent share of funding. According to Crunchbase, investments directed toward biotech companies focused on AI have exceeded $6 billion since the beginning of the year.
The sector’s largest funding round, and the largest round for a biotech company during the year, went to London-based Isomorphic Labs, which raised $2.1 billion in a Series B round. The company describes itself as an AI-first company for drug design and development.
Delaware-based Earendil Labs followed after closing a $787 million round in March to develop AI platforms that help create protein-based treatments. San Francisco-based Chai Discovery raised $400 million in a Series C round during the summer at a valuation of $3.8 billion to apply AI to drug discovery.
But large funding was not limited to companies that present themselves as AI companies. NewLimit, a longevity startup based in South San Francisco, California, raised $435 million in a Series C round in June. The company focuses on developing drugs intended to restore youthful functions in aging cells.
The Market Remains Tilted Toward Early Stages
Although the list of largest rounds tends to favor more advanced companies, the broader picture of the startup pipeline is different. Seed and early-stage rounds accounted for more than half of total investment and most of the rounds during the year, a pattern Crunchbase says also appeared in previous years.
Biotech companies in later stages often seek a public offering after a Series B or Series C round rather than raising an additional venture capital round. During 2026, examples emerged of companies listing their shares relatively early, particularly in obesity treatment and pain management.
Kailera Therapeutics, which develops oral and injectable obesity treatments, was one of the most prominent cases. The company, founded in 2024 and based in Waltham, Massachusetts, went public in April, only six months after closing a Series B round. Personalized medicine company Kardigan also began trading its shares on Nasdaq in June, after raising more than $550 million in early funding during the previous year.
Latigo Biotherapeutics, which develops non-opioid treatments for chronic pain, completed its public offering in August, about a year and a half after its Series B round. Meanwhile, older and more advanced companies continued entering the public market; Parabilis Medicines, which works on cancer treatments and is ten years old, completed the year’s largest financing of its kind when it raised a Series F round in January.
What Do These Numbers Mean for the Market?
The data shows that stable biotech funding does not reflect the sector’s isolation from market shifts, but rather its ability to maintain a steady flow of investment while most growth is concentrated in AI. The intersection between the two fields appears to have become a primary channel for attracting massive rounds, as demonstrated by the rounds raised by Isomorphic Labs, Earendil Labs and Chai Discovery.
At the same time, early-stage companies still represent the largest share of activity, while some developers are moving quickly into the stock markets instead of relying on later-stage venture capital rounds. This opens different funding and exit paths, but it does not establish that all companies can replicate these examples or that early offerings have become the general rule.
Crunchbase also points to at least 12 acquisitions of funded biotech companies, each valued at $1 billion or more, when potential earnout payments are included. Thus, exit activity in the sector is not limited to public offerings. The open question is whether the accumulated enthusiasm around AI will continue to spill over into biotech in the coming quarters, or whether funding will remain stable without a comparable expansion wave.